Close rivalries among European medical affairs teams for leading injectable type 2 diabetes mellitus therapies. Will your team come out on top?
In Europe, one medical affairs team for a leading injectable therapy for type 2 diabetes mellitus leads the way in terms of interaction frequency and overall quality of interactions, but only 1 point separates teams in spots 2-4. Can other teams close the gap? 150 diabetologists and primary care physicians from the EU5 markets (France, Germany, Italy, Spain and the UK) provide insights on several medical affairs teams, and opinions are mixed. Will targeting improvements in certain areas be enough to put your team ahead of the competition?
Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Type 2 Diabetes Mellitus [Injectables] [2018]. This report, which covers 12 major injectable therapies in the type 2 diabetes market from Sanofi, Eli Lilly, Novo Nordisk, and GlaxoSmithKline, including Abasaglar, Eperzan, Humalog, Lantus, Lyxumia, NovoRapid, Ryzodeg, Toujeo, Tresiba, Trulicity, Victoza and Xultophy, provides handy graphs and charts that show at a glance how each team is performing across 12 key medical affairs activities, and where they need to improve:
That’s actionable information you can use to turn your team into one that doctors rely on.
Interested in the US market? Click here to see the US Edition.
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:
What do doctors need?
Does your medical affairs team deliver?
What needs improvement?
We surveyed 150 diabetologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
We conducted the survey between July 2-5, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved